Buy (150 RUB)
Generate QR code
Open Access
Subscription or Fee Access
Epilepsy in alzheimer's disease: pathophysiological mechanisms and diagnostic features
https://doi.org/10.33667/2078-5631-2025-15-46-50
Abstract
Epileptic seizures in Alzheimer's disease (AD) represent a significant clinical challenge that substantially affects disease progression and patients' quality of life. This review examines current understanding of the pathophysiological mechanisms underlying paroxysmal activity in AD, including the role of β-amyloid, tau protein, and neuroinflammation. Special attention is given to novel diagnostic approaches, including biomarkers, neuroimaging techniques, and EEG monitoring protocols. The clinical features of epileptic seizures in AD, their classification, and age-related differences in manifestation are analyzed. The review addresses the problem of epilepsy underdiagnosis in AD, which reaches 70% of cases in routine clinical practice. Current diagnostic algorithms and clinical guidelines are presented. The review emphasizes the necessity of an interdisciplinary approach to diagnosis and the importance of early identification of epileptic activity as a potential marker of neurodegenerative process.
About the Authors
A. M. Azhigova
Russian University of Medicine
Russian Federation
Russian Federation
Azhigova Asya M., PhD Med, neurologist at Dept of Neurology
T. I. Konovalova
Center for Neurology, Diagnosis and Treatment of Epilepsy LLC «EpiCenter»
Russian Federation
Russian Federation
Konovalova Tatyana I., neurologist
P. N. Vlasov
Russian University of Medicine
Russian Federation
Russian Federation
Vlasov Pavel N., DM Sci (habil.), professor, head of Dept of Neurology
References
1. Born H. A. Seizures in Alzheimer's disease. Neuroscience. 2015; 286: 251–263. DOI: 10.1016/j.neuroscience.2014.11.051
2. Vossel K. A., Beagle A. J., Rabinovici G. D. et al. Seizures and Epileptiform Activity in the Early Stages of Alzheimer Disease. JAMA Neurology. 2013; 70 (9): 1158–1166. DOI: 10.1001/jamaneurol.2013.136
3. Shin J. H. Dementia Epidemiology Fact Sheet 2022. Annals of Rehabilitation Medicine. 2022; 46 (2): 53–59. DOI: 10.5535/arm.22027
4. Pandis D., Scarmeas N. Seizures in Alzheimer disease: clinical and epidemiological data. Epilepsy Currents. 2012; 12 (5): 184–187. DOI: 10.5698/1535-7511-12.5.184
5. Friedman D., Honig L. S., Scarmeas N. Seizures and epilepsy in Alzheimer's disease. CNS Neuroscience & Therapeutics. 2012; 18 (4): 285–294. DOI: 10.1111/j.17555949.2011.00251.x
6. Ripoli C., Cocco S., Li Puma D. et al. Intracellular accumulation of amyloid-β (Aβ) protein plays a major role in Aβ-induced alterations of glutamatergic synaptic transmission and plasticity. Journal of Neuroscience. 2014; 34: 12893–12903. DOI: 10.1523/ jneurosci.1201-14.2014
7. Hector A., Brouillette J. Hyperactivity Induced by Soluble Amyloid-β Oligomers in the Early Stages of Alzheimer's Disease. Frontiers in Molecular Neuroscience. 2021; 13: 600084. DOI: 10.3389/fnmol.2020.600084
8. Palop J. J., Mucke L. Network abnormalities and interneuron dysfunction in Alzheimer disease. Nature Reviews Neuroscience. 2016; 17 (12): 777–792. DOI: 10.1038/nrn.2016.141
9. Sánchez M. P., García-Cabrero A.M., Sánchez-Elexpuru G. et al. Tau-Induced Pathology in Epilepsy and Dementia: Notions from Patients and Animal Models. International Journal of Molecular Sciences. 2018; 19 (4): 1092. DOI: 10.3390/ijms19041092
10. Vezzani A., Friedman A., Dingledine R. J. The role of inflammation in epileptogenesis. Neuropharmacology. 2013; 69 16–24. DOI: 10.1016/j.neuropharm.2012.04.004
11. Sanz P., Rubio T., Garcia-Gimeno M. A. Neuroinflammation and Epilepsy: From Pathophysiology to Therapies Based on Repurposing Drugs. International Journal of Molecular Sciences. 2024; 25 (8): 4161. DOI: 10.3390/ijms25084161
12. Zarea A., Charbonnier C., Rovelet-Lecrux A. et al. Seizures in dominantly inherited Alzheimer disease. Neurology. 2016; 87 (9): 912–919. DOI: 10.1212/WNL.0000000000003048
13. Najm R., Jones E. A., Huang Y. Apolipoprotein E 4, inhibitory network dysfunction, and Alzheimer's disease. Molecular Neurodegeneration. 2019; 14 (1). 24. DOI: 10.1186/ s13024-019-0324-6
14. Hanke J. M., Schindler K. A., Seiler A. On the relationships between epilepsy, sleep, and Alzheimer's disease: A narrative review. Epilepsy & Behavior. 2022; 129: 108609. DOI: 10.1016/j.yebeh.2022.108609
15. Cretin B., Sellal F., Philippi N. et al. Epileptic prodromal Alzheimer's disease, a retrospective study of 13 new cases: expanding the spectrum of Alzheimer's disease to an epileptic variant? Journal of Alzheimer's Disease. 2016; 52: 1125–1133. DOI: 10.3233/JAD-150096
16. Rao S. C., Dove G., Cascino G. D., Petersen R. C. Recurrent seizures in patients with dementia: frequency, seizure types, and treatment outcome. Epilepsy & Behavior. 2009; 14: 118–120. DOI: 10.1016/j.yebeh.2008.08.012
17. Sarkis R. A., Dickerson B. C., Cole A. J., Chemali Z. N. Clinical and neurophysiologic characteristics of unprovoked seizures in patients diagnosed with dementia. Journal of Neuropsychiatry and Clinical Neurosciences. 2016; 28: 56–61. DOI: 10.1176/appi. neuropsych.15060143
18. Vossel K. A., Ranasinghe K. G., Beagle A. J. et al. Incidence and impact of subclinical epileptiform activity in Alzheimer's disease. Annals of Neurology. 2016; 80: 858–870. DOI: 10.1002/ana.24794
19. Horvath A. A., Papp A., Zsuffa J. et al. Subclinical epileptiform activity accelerates the progression of Alzheimer's disease: A long-term EEG study. Clinical Neurophysiology. 2021; 132 (8): 1982–1989. DOI: 10.1016/j.clinph.2021.03.050
20. Hermann P., Zerr I. Rapidly progressive dementias – aetiologies, diagnosis and management. Nature Reviews Neurology. 2022; 18 (6.): 363–376. DOI: 10.1038/s41582-022-00659-0
21. Mauricio E. A., Freeman W. D. Status epilepticus in the elderly: differential diagnosis and treatment. Neuropsychiatric Disease and Treatment. 2011; 7: 161–166. DOI: 10.2147/NDT.S 10537
22. Lezaic N., Roussy J., Masson H. et al. Epilepsy in the elderly: Unique challenges in an increasingly prevalent population. Epilepsy & Behavior. 2020; 102: 106724. DOI: 10.1016/j. yebeh.2019.106724
23. Tang M., Ryman D. C., McDade E. et al. Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). The Lancet Neurology. 2016; 15 (13): 1317–1325. DOI: 10.1016/S 1474-4422 (16) 30229-0
24. Tábuas-Pereira M., Durães J., Lopes J. et al. Increased CSF tau is associated with a higher risk of seizures in patients with Alzheimer's disease. Epilepsy & Behavior. 2019; 98 (Pt A): 207–209. DOI: 10.1016/j.yebeh.2019.06.033
25. Liew Y., Retinasamy T., Arulsamy A., Ali I., Jones N. C., O'Brien T.J., Shaikh M. F. Neuroinflammation: A Common Pathway in Alzheimer's Disease and Epilepsy. Journal of Alzheimer's Disease. 2023; 94(s1): S 253–S 265. DOI: 10.3233/JAD-230059
26. Alcantara-Gonzalez D., Villasana-Salazar B., Peña-Ortega F. Single amyloid-beta injection exacerbates 4-aminopyridine-induced seizures and changes synaptic coupling in the hippocampus. Hippocampus. 2019; 29: 1150–1164. DOI: 10.1002/hipo.23126
27. Dou W., Zhao L., Su C. et al. A quantitative MRI index for assessing the severity of hippocampal sclerosis in temporal lobe epilepsy. BMC Medical Imaging. 2020; 20: 42. DOI: 10.1186/s12880-020-00440-z
28. Saidlitz P., Voisin T., Vellas B. et al. Amyloid imaging in Alzheimer's disease: a literature review. The Journal of Nutrition, Health & Aging. 2014; 18 (7): 723–740. DOI: 10.1007/ s12603-014-0507-3
29. Krishnadas N., Villemagne V. L., Doré V., Rowe C. C. Advances in Brain Amyloid Imaging. Seminars in Nuclear Medicine. 2021; 51 (3): 241–252. DOI: 10.1053/j.semnuclmed.2020.12.005
30. Fountain N. B., Kim J. S., Lee S. I. Sleep deprivation activates epileptiform discharges independent of the activating effects of sleep. Journal of Clinical Neurophysiology. 1998. 15. 69–75. DOI: 10.1097/00004691-199801000-00009
31. Ramsay R. E., Rowan A. J., Pryor F. M. Special considerations in treating the elderly patient with epilepsy. Neurology. 2004; 62 (5, Suppl 2): P. S 24–S 29. DOI: 10.1212/ wnl.62.5_suppl_2.s24
32. Horváth A., Szűcs A., Hidasi Z. et al. Prevalence, Semiology, and Risk Factors of Epilepsy in Alzheimer's Disease: An Ambulatory EEG Study. Journal of Alzheimer's Disease. 2018; 63 (3): 1045–1054. DOI: 10.3233/JAD-170925
33. Cretin B., Philippi N., Bousiges O. et al. Do we know how to diagnose epilepsy early in Alzheimer's disease? Revue Neurologique. 2017; 173 (6): 374–380. DOI: 10.1016/j. neurol.2017.03.028
34. Devulder A., Macea J., Kalkanis A. et al. Subclinical epileptiform activity and sleep disturbances in Alzheimer's disease. Brain and Behavior. 2023; 13 (12): e3306. DOI: 10.1002/brb3.3306
35. Sen A., Jette N., Husain M., Sander J. W. Epilepsy in older people. The Lancet. 2020; 395 (10225): 735–748. DOI: 10.1016/S 0140-6736 (19) 33064-8
36. Петров В. А., Иванов С. Н., Смирнова Е. В. Клинические рекомендации по диагностике и лечению эпилепсии. Неврология. 2023; 25 (3): 45–67.
37. Petrov V. A., Ivanov S. N., Smirnova E. V. Clinical recommendations for the diagnosis and treatment of epilepsy. Neurology. 2023; 25 (3): 45–67. (In Russ.).
Review
For citations:
Azhigova A.M., Konovalova T.I., Vlasov P.N. Epilepsy in alzheimer's disease: pathophysiological mechanisms and diagnostic features. Medical alphabet. 2025;(15):46-50. (In Russ.) https://doi.org/10.33667/2078-5631-2025-15-46-50
Views:
34
Email this article 